Daniel Shipp
Family · Wentzville, MONPI 1982714853
Payments from drug & device makers
Across 307 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$983
- Novo Nordisk$785
- Lilly USA, LLC$738
- Boehringer Ingelheim$672
- Amgen$580
- AstraZeneca$355
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $983 |
| Novo Nordisk | 40 | $785 |
| Lilly USA, LLC | 39 | $738 |
| Boehringer Ingelheim | 43 | $672 |
| Amgen | 37 | $580 |
| AstraZeneca | 15 | $355 |
| Otsuka America Pharmaceutical, Inc. | 14 | $236 |
| Supernus Pharmaceuticals, Inc. | 10 | $220 |
| Lundbeck LLC | 9 | $185 |
| Pfizer | 6 | $103 |
| GSK | 6 | $89 |
| Merck | 6 | $85 |
| Exact Sciences | 4 | $80 |
| Novartis | 4 | $79 |
| Abbott | 5 | $78 |
| Sanofi-aventis U.S. LLC | 3 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Neurocrine Biosciences, Inc. | 3 | $44 |
| Dexcom, Inc. | 2 | $42 |
| Cranial Technologies, Inc | 2 | $40 |
| Mylan Specialty L.p. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Globus Medical | 1 | $19 |
| Neos Therapeutics, LP | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,701 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $64,049 |
| JardianceEmpagliflozin | 30 | $39,099 |
| MounjaroTirzepatide | 23 | $25,310 |
| EliquisApixaban | 31 | $24,686 |
| TrulicityDulaglutide | 18 | $19,385 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $9,171 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $8,489 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,570 |
| Carbamazepine ErCarbamazepine | 13 | $2,170 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $1,941 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,829 |
| Duloxetine Hcl | 71 | $1,580 |
| Atorvastatin Calcium | 198 | $1,423 |
| Celecoxib | 41 | $1,381 |
| Tamsulosin Hcl | 92 | $1,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $785 | $64,04947 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $672 | $48,27047 claims |
| Lilly USA, LLCMounjaro, Trulicity | $738 | $44,69541 claims |
| PfizerEliquis | $103 | $24,68631 claims |
| AstraZenecaSymbicort | $355 | $8,48916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Wentzville
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.